Work

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.tps370

Authors: Sumanta K. Pal, Laurence Albiges, Cristina Suarez Rodriguez, Bo Liu, Jennifer Doss, Sudha Khurana, Christian Scheffold, Martin H Voss, Toni K. Choueiri

Institutions: City Of Hope National Medical Center, City of Hope, Institut Gustave Roussy, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Genentech, Exelixis (United States), Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3133762486

Cites:

Cited by: 25

Related to: 10